Entellus Medical Secures $15 Million Financing To Commercialize a New Sinus Surgery Alternative
Summary
“We’re excited to give ENT [ear, nose and throat] doctors and their patients an alternative that reduces pain, bleeding and recovery time compared to traditional sinus surgery — and one that also eliminates the need for general anesthesia,” said Tom Ressemann, president and CEO of Entellus. Ressemann said the latest round of funding will be used to expand third-party payer reimbursements to include office settings — a first for sinus surgery. In addition, the funding will allow Entellus to launch the technology nationwide this fall — with extensive outreach, training and support for ENT surgeons to adopt the treatment. “With this new round of financing, we expect the company to be self-sustaining with the opportunity to deliver innovative and exciting technology to the ENT community,” Ressemann said. Entellus’ technological breakthrough makes it possible to treat chronic sinusitis sufferers less invasively than traditional surgery, under local instead of general anesthesia, and offers the opportunity to ultimately perform this treatment in the ENT office setting instead of the operating room.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
